Compare · JNJ vs PRFX
JNJ vs PRFX
Side-by-side comparison of Johnson & Johnson (JNJ) and PRF Technologies Ltd. (PRFX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and PRFX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $642.79B, about 197493.1x PRFX ($3.3M).
- Over the past year, JNJ is up 58.0% and PRFX is down 85.4% - JNJ leads by 143.4 points.
- JNJ has been more active in the news (15 items in the past 4 weeks vs 8 for PRFX).
- JNJ has more recent analyst coverage (25 ratings vs 0 for PRFX).
- Company
- Johnson & Johnson
- PRF Technologies Ltd.
- Price
- $265.74-0.35%
- $1.06+0.47%
- Market cap
- $642.79B
- $3.3M
- 1M return
- +2.81%
- -24.47%
- 1Y return
- +57.97%
- -85.41%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 15
- 8
- Recent ratings
- 25
- 0
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
PRF Technologies Ltd.
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
Latest JNJ
- Covista Names Emily C. Chiu and Leslie Storms to its Board of Directors
- Johnson & Johnson filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
- SEC Form 10-Q filed by Johnson & Johnson
- TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
- Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System
- EVP, Global Corp Affairs Broadhurst Vanessa exercised 23,054 shares at a strike of $130.77 and sold $5,792,686 worth of shares (23,054 units at $251.27) (SEC Form 4)
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
Latest PRFX
- SEC Form 6-K filed by PRF Technologies Ltd.
- PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms
- SEC Form 6-K filed by PRF Technologies Ltd.
- PRF Technologies to Showcase GridFeed™ at Energy Trading Week Europe 2026
- SEC Form 6-K filed by PRF Technologies Ltd.
- PRF Technologies Expands DeepSolar Predict™ Platform with Battery-to-Revenue Intelligence, Extending AI-Driven Revenue Optimization Across Solar and Energy Storage Assets
- SEC Form 6-K filed by PRF Technologies Ltd.
- PRF Technologies’ DeepSolar Successfully Validates Predict™ AI Platform for Renewable Energy Revenue Optimization Using Real-World European Market Data
- SEC Form EFFECT filed by PRF Technologies Ltd.
- SEC Form 424B3 filed by PRF Technologies Ltd.